Telavancin

MedChem Express

Telavancin

10

Research Use Only

C80H106Cl2N11O27P

1755.63

Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria[1].

ClC1=CC([C@H]([C@](C(N[C@@H]2C(O)=O)=O)([H])N3)O)=CC=C1OC4=CC([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C3=O)([H])C(C=C6C(C2=CC(O)=C7CNC[P](O)(O)=O)=C7O)=CC=C6O)=O)=CC(OC8=CC=C([C@H]([C@H]5NC([C@H](NC)CC(C)C)=O)O)C=C8Cl)=C4O[C@H](O[C@@H]9CO)[C@@H]([C@H]([C@@H]9O)O)O[C@H](O[C@H]%10C)C[C@@](C)([C@@H]%10O)NCCNCCCCCCCCCC

-20°C,2°C to 8°C

12352200